Study quantifies drug revenue invested in R&D | NHS England will pay for SMA drug Spinraza | Onconova, HanX to enter rigosertib deal in China
May 16, 2019
DIA Global SmartBrief
News on diagnostic and therapeutic innovations and regulatory science
Top Story
Study quantifies drug revenue invested in R&D
A study commissioned by the Campaign for Sustainable Rx Pricing revealed that drugmakers spend an average of 22% of revenue on research and development, reinforcing the industry's own estimate of 20%.
STAT (tiered subscription model) (5/14) 
LinkedIn Twitter Facebook Email
NHS England will pay for SMA drug Spinraza
The National Health Service England and Biogen have entered an access agreement to fund Biogen's spinal muscular atrophy drug Spinraza for a limited period to evaluate its efficacy. Details regarding the amount to be paid for the drug, which costs $750,000 for the first year and $375,000 per year thereafter in the US, weren't disclosed by NHS England.
Reuters (5/14) 
LinkedIn Twitter Facebook Email
Asia Pacific
Onconova, HanX to enter rigosertib deal in China
Onconova Therapeutics and HanX Biopharmaceuticals agreed to work together to develop and market products, including rigosertib, in China. Under the terms of the agreement, Onconova will get $6 million upfront, plus milestone payments and royalties.
Seeking Alpha (5/13) 
LinkedIn Twitter Facebook Email
Pfizer makes progress on drug collaboration with Sosei Heptares
Sosei Heptares has received a milestone payment of $3 million after Pfizer chose the first preclinical small-molecule drug targeted at G-protein coupled receptors created under the collaboration for development.
PMLive (UK) (5/14) 
LinkedIn Twitter Facebook Email
Optimize your clinical trial program with the AWS Cloud
Clinical trials bring a variety of challenges, including costs, delays and recruitment shortfalls. These challenges can be overcome with a modernized trial program that takes advantage of cloud technology, AI and machine learning. Learn more with this infographic.
North America
NIH releases interactive data browser for precision medicine research
The NIH's All of Us precision medicine research program has launched an interactive data browser that allows members of the public and researchers to access information about people who have participated in the program to date. The summary data includes EHR information, physical measurements gathered from the program's partner sites and basic demographic and lifestyle information.
Becker's Health IT & CIO Report (5/7) 
LinkedIn Twitter Facebook Email
Boehringer agrees to delay biosimilar Humira launch
AbbVie settled a patent dispute with Boehringer Ingelheim over a biosimilar version of AbbVie's Humira, or adalimumab, with Boehringer agreeing to delay US introduction until July 2023. Amgen, Fresenius Kabi, Mylan, Samsung Bioepis, Pfizer and Novartis unit Sandoz have reached similar patent settlements with AbbVie.
Crain's Chicago Business (tiered subscription model) (5/14),  Seeking Alpha (5/14) 
LinkedIn Twitter Facebook Email
FDA OKs AstraZeneca's combo diabetes drug
AstraZeneca's Qternmet XR, a combination therapy that contains dapagliflozin, metformin and saxagliptin, has been approved by the FDA as an adjunct to diet and exercise for patients with type 2 diabetes. The approval was based on the results of two Phase III trials, both of which showed significant HbA1C reductions among those given the drug.
Endocrinology Advisor (5/14) 
LinkedIn Twitter Facebook Email
Study: Chemotherapy need will increase 53% by 2040
The global need for chemotherapy treatment is estimated to increase 53% by 2040, and more cancer physicians will be needed, according to a study published in The Lancet Oncology. "Strategies are urgently needed to equip the global health workforce to enable safe treatment of current and future patients," said Brooke Wilson, the study's lead author.
Specialty Pharmacy Times (5/13) 
LinkedIn Twitter Facebook Email
DIA News
Advance Discovery Science for Public Health Impact
How can we advance discovery science for public health impact? Gary Gibbons, MD, Director of the National Heart, Lung and Blood Institute (NHLB) at the National Institutes of Health, will address that question and more as he delivers the keynote address at the DIA 2019 Global Annual Meeting in San Diego. Gain valuable skills and insights, discover the latest breakthroughs, and network with more than 7,000 peers and colleagues at the largest life-sciences event of its kind! With more than 250 sessions, 13 core interest areas, and 450 exhibitors, there's something for everyone - check out our program today!
LinkedIn Twitter Facebook Email
Shake up your mental processes
Need a new way of thinking or just looking to stimulate your creativity? DIA has a solution! Take your learning to a new level by attending one of our many life sciences events, held around the globe. Check out our upcoming, can't-miss meetings for health care and life sciences professionals:
LinkedIn Twitter Facebook Email
Display images to show real-time content
Learn more about DIA:
About DIA | Meetings & Trainings | News & Publications | Membership
Press Releases
Post a Press Release
I've never really taken anything very seriously. I enjoy life because I enjoy making other people enjoy it.
Tim Conway,
comedian, actor, writer and director


LinkedIn Twitter Facebook Email
Sign Up
SmartBrief offers 200+ newsletters
Learn more about the SmartBrief audience
Subscriber Tools:
Contact Us:
Advertising  -  Sarah Hostetler
Editor  -  Nicole Brown
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2019 SmartBrief, Inc.®
Privacy Policy (updated May 25, 2018) |  Legal Information